Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network

被引:50
作者
Susukida, Ryoko [1 ]
Crum, Rosa M. [1 ,2 ,3 ]
Stuart, Elizabeth A. [1 ]
Ebnesajjad, Cyrus [1 ]
Mojtabai, Ramin [1 ,3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 North Broadway Room 897, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
关键词
Clinical trials; sample representativeness; substance use disorders; MOTIVATIONAL ENHANCEMENT THERAPY; BUPRENORPHINE-NALOXONE; SOCIOECONOMIC-STATUS; SUBSTANCE-ABUSE; GENERALIZABILITY; DEPENDENCE; INCENTIVES; PREDICTORS; EDUCATION; SELECTION;
D O I
10.1111/add.13327
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To compare the characteristics of individuals participating in randomized controlled trials (RCTs) of treatments of substance use disorder (SUD) with individuals receiving treatment in usual care settings, and to provide a summary quantitative measure of differences between characteristics of these two groups of individuals using propensity score methods. Design Analyses using data from RCT samples from the National Institute of Drug Abuse Clinical Trials Network (CTN) and target populations of patients drawn from the Treatment Episodes Data Set-Admissions (TEDS-A). Settings Multiple clinical trial sites and nation-wide usual SUD treatment settings in the United States. Participants A total of 3592 individuals from 10 CTN samples and 1 602 226 individuals selected from TEDS-A between 2001 and 2009. Measurements The propensity scores for enrolling in the RCTs were computed based on the following nine observable characteristics: sex, race/ethnicity, age, education, employment status, marital status, admission to treatment through criminal justice, intravenous drug use and the number of prior treatments. Findings The proportion of those with >= 12 years of education and the proportion of those who had full-time jobs were significantly higher among RCT samples than among target populations (in seven and nine trials, respectively, at P < 0.001). The pooled difference in the mean propensity scores between the RCTs and the target population was 1.54 standard deviations and was statistically significant at P < 0.001. Conclusions In the United States, individuals recruited into randomized controlled trials of substance use disorder treatments appear to be very different from individuals receiving treatment in usual care settings. Notably, RCT participants tend to have more years of education and a greater likelihood of full-time work compared with people receiving care in usual care settings.
引用
收藏
页码:1226 / 1234
页数:9
相关论文
共 50 条
[31]   The therapeutic alliance in randomized controlled clinical trials [J].
Kossoy, A ;
Wilner, PJ .
FORSCHENDE KOMPLEMENTARMEDIZIN, 1998, 5 :31-36
[32]   Quantifying representativeness in randomized clinical trials using machine learning fairness metrics [J].
Qi, Miao ;
Cahan, Owen ;
Foreman, Morgan A. ;
Gruen, Daniel M. ;
Das, Amar K. ;
Bennett, Kristin P. .
JAMIA OPEN, 2021, 4 (03)
[33]   National Cancer Institute Clinical Trials Program in Colorectal Cancer [J].
Barbara A. Conley ;
Richard S. Kaplan ;
Susan G. Arbuck .
Cancer Chemotherapy and Pharmacology, 1998, 42 :S75-S79
[34]   Single versus multiple drug focus in substance abuse clinical trials research: the devil is in the details [J].
Strain, EC .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (02) :131-134
[35]   National Cancer Institute Clinical Trials Program in colorectal cancer [J].
Conley, BA ;
Kaplan, RS ;
Arbuck, SG .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (Suppl 1) :S75-S79
[36]   Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials [J].
Sharma, Shubham ;
Wells, J. Connor ;
Hopman, Wilma M. ;
Del Paggio, Joseph C. ;
Gyawali, Bishal ;
Hammad, Nazik ;
Hay, Annette E. ;
Booth, Christopher M. .
CURRENT ONCOLOGY, 2021, 28 (02) :1518-1527
[37]   Expanding the National Drug Abuse Treatment Clinical Trials Network to address the management of substance use disorders in general medical settings [J].
Tai, Betty ;
Sparenborg, Steven ;
Ghitza, Udi E. ;
Liu, David .
SUBSTANCE ABUSE AND REHABILITATION, 2014, 5 :75-80
[38]   Fundamentals of Conducting Cooperative Group Trials Through the National Clinical Trials Network [J].
Snyder, Rebecca A. ;
Katz, Matthew H. G. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 32 (01) :1-12
[39]   Technology transfer for the implementation of a clinical trials network on drug abuse and mental health treatment in Mexico [J].
Horigian, Viviana E. ;
Marin-Navarrete, Rodrigo A. ;
Verdeja, Rosa E. ;
Alonso, Elizabeth ;
Perez, Maria A. ;
Fernandez-Mondragon, Jose ;
Berlanga, Carlos ;
Elena Medina-Mora, Maria ;
Szapocznik, Jose .
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2015, 38 (03) :233-242
[40]   The proportion of randomized controlled trials that inform clinical practice [J].
Hutchinson, Nora ;
Moyer, Hannah ;
Zarin, Deborah A. ;
Kimmelman, Jonathan .
ELIFE, 2022, 11